Bachem's Pharma global headquarters is located in Bubendorf, Switzerland, serves as the international headquarters, responsible for overall strategy and public relations. The operating entity, is also based in Bubendorf and manages product development and manufacturing for Europe, USA, Africa, India, and the Middle East.
The GMP site in Garland, Texas, was founded in 2005 and acquired by USA USA Bachem Pharma in 2025. It is the center of excellence for the American organization in the development of new chemical entities (NCEs), with in-depth knowledge and expertise in chemistry, manufacturing, and controls (CMC) to achieve successful commercialization. Together with state-of-the-art equipment and a rapidly growing degree of automation, the Garland site delivers efficient peptide active pharmaceutical ingredient (API) development and manufacturing on a small to medium scale
The Houston location manufactures commercial API, peptides capsules, new chemical entities (NCEs), and intermediates using state-of-the-art equipment and facilities. Since its acquisition, the site has undergone significant capacity expansion to meet the market demand for peptide products at the medium and larger scale. The site also provides custom synthesis for research-grade peptides
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.